N-Acetylcysteine /tab

Phase 3Small molecule

FFar Eastern Memorial Hospital

N-Acetylcysteine /tab is one of 11 small molecule programs targeting Mucositis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MucositisActive, not recruiting

MucositisPhase 3

Active, not recruiting

Competition

Competitive Landscape

13 competitors in Mucositis

#DrugCompanyPhaseTrials

Galzin

AAmerican Regent, Inc.

Approved

1 2

Dilaudid

RRhodes Pharmaceuticals, L.P.

Approved

—3

Ethyol

LLegacy Health System

Approved

—4

Kenalog

BBausch Health Americas, Inc.

Tylenol

Neo-Synephrine

EExela Pharma Sciences, LLC.

Approved

—7

N-Acetylcysteine /tab

FFar Eastern Memorial Hospital

Phase 3

1 8

Peridex

DDexcel Pharma Technologies Ltd.

Preclinical

1 9

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 10

Kepivance

SSwedish Orphan Biovitrum

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Mucositis1 trial

Safety and Efficacy of N-Acetylcysteine Mouthwash in Prevention of Mucositis in HSCT Patients

Active, not recruiting·TTehran University of Medical Sciences·Phase 3·NCT07325383·106 enrolled

Cardiopulmonary Bypass1 trial

Acetylcysteine Against Acute Renal Insult During Cardiopulmonary Bypass.

Suspended·FFar Eastern Memorial Hospital·Phase 4·NCT00190034·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for N-Acetylcysteine /tab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — N-Acetylcysteine /tab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for N-Acetylcysteine /tab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Far Eastern Memorial Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: FFar Eastern Memorial Hospital

N-Acetylcysteine /tab

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Mucositis1 trial

Cardiopulmonary Bypass1 trial

References

Drug Info

Quick Facts

Related News